Please ensure Javascript is enabled for purposes of website accessibility

Tandem Diabetes Care Posts Surprise Q4 Profit

By Eric Volkman - Feb 25, 2020 at 6:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Despite the unexpected result, the company's stock price sank on the day.

Tandem Diabetes Care (TNDM 0.62%) followed the broader market and traded down on Tuesday, despite reporting quarterly results that featured an unexpected bottom-line profit.

The company, which makes insulin pumps and related products to help treat diabetes, booked sales of almost $108.4 million in its Q4 of fiscal 2019, which was 42% higher on a year-over-year basis. Net income fell to just under $2.7 million ($0.04 per share), from Q4 of fiscal 2018's nearly $3.7 million.

Vial of insulin with stethoscope.

Image source: Getty Images.

This produced a mixed quarter in relation to analyst estimates. Prognosticators following the stock had collectively anticipated a top-line result of $109 million but were expecting a net loss equating to $0.07 per share.

Tandem's sales have been rising precipitously thanks to its popular signature product line, the t:slim X2 insulin pump.

Sales growth of 42% in Q4 is down quite a bit from Q3's near doubling; according to Tandem this is due to clients who are waiting for the company's latest innovation to be approved by the Food and Drug Administration for use with the t:slim X2s. Called Control-IQ, this is a digital program that adjusts insulin levels for patients using those products.

The company also proffered guidance. It is forecasting sales of $450 million to $465 million, which would mean at least a 24% improvement on the fiscal 2019 result of $362 million. Adjusted EBITDA should land at 12% to 14% of sales; in 2019 this percentage landed at 13%.

Previous to this week's bear market, Tandem shares had generally been rising sharply. Even with Tuesday's 10%-plus decline, the healthcare stock is still up by almost 29% year to date.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tandem Diabetes Care Stock Quote
Tandem Diabetes Care
$53.89 (0.62%) $0.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.